You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Sildenafil citrate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for sildenafil citrate and what is the scope of freedom to operate?

Sildenafil citrate is the generic ingredient in four branded drugs marketed by Viatris, Ajanta Pharma Ltd, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Granules, Hetero Labs Ltd V, Invagen Pharms, Lupin Ltd, MSN, Novitium Pharma, Somerset Theraps Llc, Taro, Teva Pharms Usa, Tris Pharma Inc, Zydus Lifesciences, Eugia Pharma, Cmp Dev Llc, Actavis Grp Ptc, Amneal Pharms Ny, Apotex Corp, Appco, Cadila Pharms Ltd, Chartwell Rx, Macleods Pharms Ltd, Mylan, Mylan Pharms Inc, Perrigo R And D, Reyoung, Rubicon, Sunshine, Teva, Teva Pharms, Torrent, Torrent Pharms Ltd, Umedica, and Watson Labs Inc, and is included in fifty-two NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sildenafil citrate has nine patent family members in nine countries.

There are eighteen drug master file entries for sildenafil citrate. Sixty-eight suppliers are listed for this compound. There are three tentative approvals for this compound.

Drug Prices for sildenafil citrate

See drug prices for sildenafil citrate

Drug Sales Revenue Trends for sildenafil citrate

See drug sales revenues for sildenafil citrate

Recent Clinical Trials for sildenafil citrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Batterjee Medical CollegePhase 4
University of PennsylvaniaPhase 2
Ladoke Akintola University of Technology Teaching Hospital, OgbomosoPhase 4

See all sildenafil citrate clinical trials

Generic filers with tentative approvals for SILDENAFIL CITRATE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up100MGTABLET; ORAL
⤷  Sign Up⤷  Sign Up50MGTABLET; ORAL
⤷  Sign Up⤷  Sign Up25MGTABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for sildenafil citrate
Medical Subject Heading (MeSH) Categories for sildenafil citrate
Anatomical Therapeutic Chemical (ATC) Classes for sildenafil citrate
Paragraph IV (Patent) Challenges for SILDENAFIL CITRATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIAGRA Tablets sildenafil citrate 25 mg and 50 mg 020895 1 2004-11-19
VIAGRA Tablets sildenafil citrate 100 mg 020895 1 2004-10-25

US Patents and Regulatory Information for sildenafil citrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rubicon SILDENAFIL CITRATE sildenafil citrate TABLET;ORAL 204882-001 Jun 11, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms Ny SILDENAFIL CITRATE sildenafil citrate TABLET;ORAL 202023-003 Jun 27, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan SILDENAFIL CITRATE sildenafil citrate TABLET;ORAL 201171-001 Mar 25, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Taro SILDENAFIL CITRATE sildenafil citrate FOR SUSPENSION;ORAL 215522-001 Nov 16, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for sildenafil citrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris REVATIO sildenafil citrate SOLUTION;INTRAVENOUS 022473-001 Nov 18, 2009 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for sildenafil citrate

Country Patent Number Title Estimated Expiration
Australia 2018397436 Liquid oral formulations for PDE V inhibitors ⤷  Sign Up
Morocco 50320 Formulations orales liquides pour inhibiteurs de pde v ⤷  Sign Up
Singapore 11202006080S LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS ⤷  Sign Up
European Patent Office 3731870 FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for sildenafil citrate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0463756 SPC/GB99/004 United Kingdom ⤷  Sign Up PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756 C990005 Netherlands ⤷  Sign Up PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756 5/1999 Austria ⤷  Sign Up PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756 99C0007 Belgium ⤷  Sign Up PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.